Finance News – Prescriptions
What is your interest today?
Bitcoin
Crypto
Btc
Ceo
Tariffs
Stocks
Crypto Assets
Investors
Cryptocurrency
Stock
Shares
Stock Market
Ethereum
Price
Markets
Xrp
Investment
Blockchain
Etf
Sec
Stablecoin
Eth
Trade
Earnings
Bse
Index
Solana
Ipo
Revenue
China
Coinbase
Token
Inflation
Wall Street
Nasdaq
Interest Rates
Trade War
Sensex
Usd
Economy
Tesla
Profit
Digital Assets
Nse
Gold
Traders
Sp 500
Treasury
Bse Sensex
Federal Reserve
Network
Bharat Electronics
Us Steel
Financial Health
Ottawa
Collateralized Loan Obligations
Indian Listings
Parcel Revenue
Treasury Rates
Lalithaa Jewellery Mart
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Quartz • May 30, 2025
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →
The Guardian – Business • May 07, 2025
Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
Novo Nordisk's reduced earnings outlook reflects challenges in maintaining sales momentum for its obesity treatment, as competitive pressures from US rivals increasingly impact its...
Read Full Article →